Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 1
1977 2
1978 4
1979 4
1980 3
1981 3
1982 2
1983 5
1984 3
1985 6
1986 7
1987 3
1988 5
1989 4
1990 5
1991 6
1992 10
1993 5
1994 9
1995 9
1996 6
1997 6
1998 2
1999 6
2000 6
2001 1
2002 5
2003 4
2004 7
2005 11
2006 7
2007 2
2008 5
2009 5
2010 5
2011 3
2012 4
2013 1
2014 2
2015 2
2016 4
2017 2
2018 4
2019 3
2020 2
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK. Sikic BI, et al. J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811285 Free PMC article. Clinical Trial.
Pulmonary toxicity of antitumor agents.
Muggia FM, Louie AC, Sikic BI. Muggia FM, et al. Among authors: sikic bi. Cancer Treat Rev. 1983 Dec;10(4):221-43. doi: 10.1016/0305-7372(83)90012-9. Cancer Treat Rev. 1983. PMID: 6198083 Review. No abstract available.
The reversal of multidrug resistance.
Fisher GA, Lum BL, Sikic BI. Fisher GA, et al. Among authors: sikic bi. Cancer Treat Res. 1995;78:45-70. doi: 10.1007/978-1-4615-2007-8_3. Cancer Treat Res. 1995. PMID: 8595147 Review. No abstract available.
Multidrug resistance in lymphomas.
Yuen AR, Sikic BI. Yuen AR, et al. Among authors: sikic bi. J Clin Oncol. 1994 Nov;12(11):2453-9. doi: 10.1200/JCO.1994.12.11.2453. J Clin Oncol. 1994. PMID: 7964963 Review.
Antitumor antibiotics.
Sikic BI. Sikic BI. Curr Opin Oncol. 1989 Dec;1(2):198-202. Curr Opin Oncol. 1989. PMID: 2489960 Review. No abstract available.
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T. Sanborn RE, et al. Among authors: sikic bi. J Immunother Cancer. 2022 Aug;10(8):e005147. doi: 10.1136/jitc-2022-005147. J Immunother Cancer. 2022. PMID: 35940825 Free PMC article.
Anticancer drug discovery.
Sikic BI. Sikic BI. J Natl Cancer Inst. 1991 Jun 5;83(11):738-40. doi: 10.1093/jnci/83.11.738. J Natl Cancer Inst. 1991. PMID: 2041045 No abstract available.
Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.
Pernar Kovač M, Tadić V, Kralj J, Duran GE, Stefanelli A, Stupin Polančec D, Dabelić S, Bačić N, Tomicic MT, Heffeter P, Sikic BI, Brozovic A. Pernar Kovač M, et al. Among authors: sikic bi. Cell Mol Life Sci. 2023 Sep 17;80(10):294. doi: 10.1007/s00018-023-04943-0. Cell Mol Life Sci. 2023. PMID: 37718345 Free PMC article.
197 results